These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26641027)

  • 1. The Triumph of Innovation and the Hard Work of Caring for Patients With Diabetes.
    Montori VM; Rodriguez-Gutierrez R
    Ann Intern Med; 2016 Jan; 164(2):127-8. PubMed ID: 26641027
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner.
    McCarthy M
    BMJ; 2015 Dec; 351():h6702. PubMed ID: 26656272
    [No Abstract]   [Full Text] [Related]  

  • 3. Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?
    Pratley RE
    Diabetes Technol Ther; 2016 Nov; 18(11):671-673. PubMed ID: 27860501
    [No Abstract]   [Full Text] [Related]  

  • 4. [Not Available].
    Fischli S; Henzen C
    Ther Umsch; 2017; 74(8):433-439. PubMed ID: 29461151
    [No Abstract]   [Full Text] [Related]  

  • 5. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1 receptor agonist confer target organ protection in type 2 diabetes.
    Bonnet F
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S1-2S2. PubMed ID: 28431665
    [No Abstract]   [Full Text] [Related]  

  • 7. New Injectable Drug for Type 2 Diabetes.
    Aschenbrenner DS
    Am J Nurs; 2016 Nov; 116(11):22-23. PubMed ID: 27787319
    [No Abstract]   [Full Text] [Related]  

  • 8. [GLP-1 receptor agonists: current state].
    Larger É; Dehghani L; Saatdjian L; Wucher H
    Rev Prat; 2015 Oct; 65(8):1037-8. PubMed ID: 26749700
    [No Abstract]   [Full Text] [Related]  

  • 9. Lixisenatide for type 2 diabetes.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):19-21. PubMed ID: 28118649
    [No Abstract]   [Full Text] [Related]  

  • 10. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Pfeffer MA; Claggett B; Probstfield JL
    N Engl J Med; 2016 Mar; 374(11):1095-6. PubMed ID: 26981945
    [No Abstract]   [Full Text] [Related]  

  • 11. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Tsutsumi Y; Tsujimoto Y; Ikenoue T
    N Engl J Med; 2016 Mar; 374(11):1094-5. PubMed ID: 26981946
    [No Abstract]   [Full Text] [Related]  

  • 12. [Not Available].
    Salvador J; Gaztambide S
    Med Clin (Barc); 2014; 143 Suppl 2():1. PubMed ID: 25326835
    [No Abstract]   [Full Text] [Related]  

  • 13. Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients?
    Maiza JC; Gérard P; Rollot O; Cogne M; Jarlet E; Schneebeli S
    Minerva Endocrinol; 2016 Mar; 41(1):138-40. PubMed ID: 26878563
    [No Abstract]   [Full Text] [Related]  

  • 14. Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).
    Nunez DJ; D'Alessio D
    Diabetes Obes Metab; 2018 Feb; 20(2):233-237. PubMed ID: 28842950
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetes: Lixisenatide does not increase rates of CVD events.
    Huynh K
    Nat Rev Cardiol; 2016 Feb; 13(2):63. PubMed ID: 26701217
    [No Abstract]   [Full Text] [Related]  

  • 16. Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Jan; 60(1539):19-21. PubMed ID: 29364197
    [No Abstract]   [Full Text] [Related]  

  • 17. [Not Available].
    Wachter J
    MMW Fortschr Med; 2024 Jun; 166(10):11. PubMed ID: 38806898
    [No Abstract]   [Full Text] [Related]  

  • 18. Glucagon-like Peptide 1 Receptor Agonist: Balancing Alarm and Caution.
    Ziemssen F; Hammes HP; Helbig H
    Klin Monbl Augenheilkd; 2024 Sep; 241(9):1021-1022. PubMed ID: 39284357
    [No Abstract]   [Full Text] [Related]  

  • 19. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
    Baron HL
    J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.